UroGen Pharma to Present at Upcoming Investor Conferences
29 Agosto 2024 - 2:00PM
Business Wire
- H.C. Wainwright 26th Annual Global Investment
Conference -
- 2024 Cantor Global Healthcare Conference
-
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated
to developing and commercializing innovative solutions that treat
urothelial and specialty cancers, today announced that it will
participate in fireside chats at the following investor conferences
in September:
H.C. Wainwright 26th Annual Global Investment Conference –
September 9-11th, 2024 Fireside Chat: September 9th, 2024 at
9:00am ET Location: New York, NY Webcast Registration Link:
Here
2024 Cantor Global Healthcare Conference – September 17-19th,
2024 Fireside Chat: September 18, 2024 at 3:40pm ET Location:
New York, NY Webcast Registration Link: Here
A webcast from the conference will also be available via the
Investors section of UroGen’s website, www.urogen.com. A replay of
the webcast will be available for approximately 90 days.
About UroGen Pharma Ltd.
UroGen is a biotech company dedicated to developing and
commercializing innovative solutions that treat urothelial and
specialty cancers because patients deserve better options. UroGen
has developed RTGel® reverse-thermal hydrogel, a proprietary
sustained-release, hydrogel-based platform technology that has the
potential to improve the therapeutic profiles of existing drugs.
UroGen’s sustained release technology is designed to enable longer
exposure of the urinary tract tissue to medications, making local
therapy a potentially more effective treatment option. Our first
product to treat low-grade upper tract urothelial cancer and
investigational treatment UGN-102 (mitomycin) for intravesical
solution for patients with LG-IR-NMIBC are designed to ablate
tumors by non-surgical means. UroGen is headquartered in Princeton,
NJ with operations in Israel. Visit www.UroGen.com to learn more or
follow us on X (Twitter), @UroGenPharma.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240829971223/en/
INVESTOR CONTACT:
Vincent Perrone Senior Director, Investor Relations
vincent.perrone@urogen.com 609-460-3588 ext. 1093
MEDIA CONTACT:
Cindy Romano Director, Corporate Communications
cindy.romano@urogen.com 609-460-3583 ext. 1083
Grafico Azioni UroGen Pharma (NASDAQ:URGN)
Storico
Da Ott 2024 a Nov 2024
Grafico Azioni UroGen Pharma (NASDAQ:URGN)
Storico
Da Nov 2023 a Nov 2024
